<DOC>
	<DOCNO>NCT01595295</DOCNO>
	<brief_summary>This registry set collect real-world experience management patient myeloid neoplasm , particularly patient MDS , CMML AML , treat hypomethylating agent Austria potentially participate country . This registry collect data retrospective well prospective manner various site . The aim gain valuable insight efficacy toxicity drug routine clinical setting patient various comorbidities .</brief_summary>
	<brief_title>Registry Hypomethylating Agents Myeloid Neoplasms</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<criteria>Patients MDS , CMML , AML begin already receive treatment hypomethylating agent willing provide inform consent Due noninterventional design program specific exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>CMML</keyword>
	<keyword>MDS</keyword>
	<keyword>AML</keyword>
	<keyword>registry</keyword>
	<keyword>Vidaza</keyword>
</DOC>